Literature DB >> 12044978

Complement 3 deficiency and oral prednisolone improve strength and prolong survival of laminin alpha2-deficient mice.

Anne M Connolly1, Richard M Keeling, Elizabeth M Streif, Alan Pestronk, Shobhna Mehta.   

Abstract

Complement deposition and macrophages are common in biopsies of children with muscular dystrophy. While the presumed roles of complement and macrophages have been those of scavenger to remove and clear necrotic fibers, there is some evidence that they play a primary role in the pathogenesis of these diseases. Here, we explore the role of complement in the pathogenesis of the most severe animal model of congenital dystrophy, the dy-/- mouse, which is laminin alpha2-deficient. We generated animals deficient in both C3 and laminin alpha2. C3 is the third component of the complement cascade and is required for activation of either the classical or alternative pathways. Thirty-three percent of the dy-/-:C3+ mice (n=59) died before 24 weeks while only 14% of the dy-/-:C3-/- (n=29) mice died (p=0.04). Absolute forepaw strength was 25-30% greater for the dy-/-:C3-/- mice up to 20 weeks of age (p<0.05 compared to complement-sufficient). Forepaw strength adjusted for weight also showed significant differences with C3-/- mice being stronger up to 20 weeks (p<0.05). However, by 24 weeks, the two groups did not differ for strength. Next, we treated 20 mice with twice weekly oral prednisolone. Survival at 24 weeks for the prednisolone treated dy-/- mice (C3-/- or C3+) was 90% (p=0.04). This work shows that complement insufficiency and weekly prednisone prolong survival and improve strength of the laminin alpha2-deficient mouse. This work suggests that the complement system may contribute directly to the pathogenesis of this form of dystrophy. Because complement activity may be modified pharmacologically, this work may have implications for treatment of children with congenital muscular dystrophy secondary to laminin alpha2 deficiency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044978     DOI: 10.1016/s0165-5728(02)00104-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  Proinflammatory signals and the loss of lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the early pathogenesis of laminin alpha2-deficient skeletal muscle.

Authors:  Katherine E Wardrop; Janice A Dominov
Journal:  J Histochem Cytochem       Date:  2011-02       Impact factor: 2.479

2.  Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-α2-deficient mouse model of congenital muscular dystrophy.

Authors:  Sachiko Homma; Mary Lou Beermann; Jeffrey Boone Miller
Journal:  Hum Mol Genet       Date:  2011-04-19       Impact factor: 6.150

3.  PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium.

Authors:  Joëlle Dupont; Jean Pierre Renou; Moshe Shani; Lothar Hennighausen; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

4.  Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy.

Authors:  Mahasweta Girgenrath; Janice A Dominov; Christine A Kostek; Jeffrey Boone Miller
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

5.  Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy.

Authors:  Mahasweta Girgenrath; Mary Lou Beermann; Vivek K Vishnudas; Sachiko Homma; Jeffrey Boone Miller
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

6.  Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.

Authors:  Rui Xu; Kumaran Chandrasekharan; Jung Hae Yoon; Marybeth Camboni; Paul T Martin
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 7.  Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies.

Authors:  Peter D Yurchenco; Karen K McKee; Judith R Reinhard; Markus A Rüegg
Journal:  Matrix Biol       Date:  2017-11-27       Impact factor: 11.583

8.  Diseased muscles that lack dystrophin or laminin-alpha2 have altered compositions and proliferation of mononuclear cell populations.

Authors:  Mahasweta Girgenrath; Christine A Kostek; Jeffrey Boone Miller
Journal:  BMC Neurol       Date:  2005-04-07       Impact factor: 2.474

9.  Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.

Authors:  Kinga I Gawlik; Johan Holmberg; Martina Svensson; Mikaela Einerborg; Bernardo M S Oliveira; Tomas Deierborg; Madeleine Durbeej
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

10.  Gene expression profiling identifies molecular pathways associated with collagen VI deficiency and provides novel therapeutic targets.

Authors:  Sonia Paco; Susana G Kalko; Cristina Jou; María A Rodríguez; Joan Corbera; Francesco Muntoni; Lucy Feng; Eloy Rivas; Ferran Torner; Francesca Gualandi; Anna M Gomez-Foix; Anna Ferrer; Carlos Ortez; Andrés Nascimento; Jaume Colomer; Cecilia Jimenez-Mallebrera
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.